---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-26-000058"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2026-07-28T20:05:51+00:00"
generated_at: "2026-07-28T20:07:07.013364+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q2 revenue up 11% to $202M; raises FY2026 guidance; settles DOJ matter

## Summary
- Total revenue $202M (+11% YoY); clinical revenue $187M (+14%); NGS revenue +26%.
- GAAP net income $2M (incl. $11M debt extinguishment gain) vs net loss $45M in Q2 2025.
- Adjusted EBITDA $14M (+36% YoY); company raises full-year 2026 revenue and adjusted EBITDA guidance.
- Completed $316M 0.75% convertible notes due 2032; repurchased $276M of existing 0.25% notes and $25M of common stock.
- Finalized civil settlement with DOJ regarding consulting services; self-disclosed matter resolved.

## SEC filing metadata
- accession: 0001077183-26-000058
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2026-07-28T20:05:51+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/0001077183-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/neo-20260728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-26-000058
- JSON: https://secwatch.observer/filing/0001077183-26-000058.json
- Plain text: https://secwatch.observer/filing/0001077183-26-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.